Literature DB >> 11868612

Involvement of hypoxia-inducible factor 1 in human cancer.

Gregg L Semenza1.   

Abstract

Hypoxia-inducible factor 1 (HIF-1) mediates transcriptional responses to hypoxia. HIF-1 is composed of an O2- and growth factor-regulated HIF-1alpha subunit and a constitutively-expressed HIF-1beta subunit. Four lines of evidence indicate that HIF-1 contributes to tumor progression. First, HIF-1 controls the expression of gene products that stimulate angiogenesis, such as vascular endothelial growth factor, and promote metabolic adaptation to hypoxia, such as glucose transporters and glycolytic enzymes, thus providing a molecular basis for involvement of HIF-1 in tumor growth and angiogenesis. Second, in mouse xenograft models, tumor growth and angiogenesis are inhibited by loss of HIF-1 activity and stimulated by HIF-1alpha overexpression. Third, immunohistochemical analyses of human tumor biopsies indicate that HIF-1alpha is overexpressed in common cancers and that the level of expression is correlated with tumor grade, angiogenesis, and mortality. Fourth, in addition to intratumoral hypoxia, genetic alterations in tumor suppressor genes and oncogenes induce HIF-1 activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11868612     DOI: 10.2169/internalmedicine.41.79

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  60 in total

1.  Anemia in cervical cancer patients: implications for iron supplementation therapy.

Authors:  Myrna Candelaria; Lucely Cetina; Alfonso Dueñas-González
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Expression and clinical implication of HIF-1alpha and VEGF-C in non-small cell lung cancer.

Authors:  Shunqing Zuo; Yanmei Ji; Jianjun Wang; Jialong Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

3.  Regulation of glycolysis in head and neck squamous cell carcinoma.

Authors:  Dhruv Kumar
Journal:  Postdoc J       Date:  2017-01

4.  Pharmacological stimulation of hypoxia inducible factor-1α facilitates the corticosterone response to a mild acute stressor.

Authors:  Constance S Harrell; Sydney A Rowson; Gretchen N Neigh
Journal:  Neurosci Lett       Date:  2015-05-29       Impact factor: 3.046

Review 5.  Regenerative medicine for the heart: perspectives on stem-cell therapy.

Authors:  Gun-Sik Cho; Laviel Fernandez; Chulan Kwon
Journal:  Antioxid Redox Signal       Date:  2014-09-22       Impact factor: 8.401

6.  Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).

Authors:  Yu-Chen Cai; Yong Zou; Yan-Li Ye; Hong-Yi Sun; Quan-Guan Su; Zhi-Xin Wang; Zhao-Lei Zeng; Li-Jian Xian
Journal:  Invest New Drugs       Date:  2009-12-11       Impact factor: 3.850

7.  HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression.

Authors:  Jacqueline Kessler; Antje Hahnel; Henri Wichmann; Swetlana Rot; Matthias Kappler; Matthias Bache; Dirk Vordermark
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

8.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

9.  Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.

Authors:  Lei Huang; Qilin Ao; Qinghua Zhang; Xiaokui Yang; Hui Xing; Fang Li; Gang Chen; Jianfeng Zhou; Shixuan Wang; Gang Xu; Li Meng; Yunping Lu; Ding Ma
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

10.  Molecular mechanisms of HIF-1alpha modulation induced by oxygen tension and BMP2 in glioblastoma derived cells.

Authors:  Francesca Pistollato; Elena Rampazzo; Sara Abbadi; Alessandro Della Puppa; Renato Scienza; Domenico D'Avella; Luca Denaro; Geertruy Te Kronnie; David M Panchision; Giuseppe Basso
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.